CMS taps Verily, Noom, 150+ others to participate in ACCESS model

CMS selected more than 150 healthcare organizations, including Verily Health, Noom, Withings Medical Group, HealthTap and Weight Watchers, for its 10-year ACCESS outcomes-based payment model set to start July 5, 2026. The program creates recurring Outcome-Aligned Payments tied to chronic-care outcomes across four tracks: hypertension, diabetes, chronic musculoskeletal pain and depression, with first-year payments of $180-$360 and ongoing care payments of $90-$210 per patient. The framework is a constructive development for digital chronic-care providers, though reimbursement rates and Medicare enrollment requirements remain key constraints.

Analysis

This is a meaningful policy de-risking event for digital chronic-care platforms, but the first-order beneficiary is actually the payer stack, not the care-delivery names. CMS is effectively creating a regulated demand floor for outcomes-based virtual management, which should improve monetization visibility for Medicare-adjacent programs and accelerate contracting leverage for insurers that can route members into lower-cost digital pathways. The key second-order effect is that reimbursement legitimacy should compress customer acquisition costs for the best-capitalized platforms while quietly raising the bar for smaller point-solution vendors that lack compliance, reporting, and longitudinal outcomes infrastructure.

The real winner set is likely the intermediary platforms with broad disease coverage and payer distribution, because they can absorb the fixed costs of Medicare enrollment, data security, and measurement. That should favor companies able to bundle navigation, coaching, RPM, and behavioral support into a single contract; it is less attractive for narrow app vendors whose economics depended on employer willingness to pay without hard outcomes proof. Over the next 6-18 months, expect a wave of partnership/roll-up activity as incumbents buy their way into the required operating stack rather than build it organically.

The biggest near-term risk is not demand but pricing. The announced payment bands look like a pilot tariff, not a fully economic reimbursement schedule, so margin realization may disappoint until utilization, adherence, and downstream medical-cost offsets are proven. If early cohorts show weak adherence or noisy outcome attribution, CMS could tighten eligibility or slow expansion, which would hit the category multiple before it hits revenue.

The market is probably underestimating how much this helps the managed-care names strategically. If payer-aligned digital chronic care reduces avoidable utilization even modestly, the benefit accrues through lower medical trend rather than immediate fee-for-service revenue, which is hard for the market to model and therefore undercapitalized in estimates. That creates a favorable setup for payers with scale and care-management infrastructure, while the pure-play digital health valuation uplift may be capped unless they can show repeatable Medicare unit economics within 2-3 quarters of launch.

Key Decisions for Investors

• Long HUM / CI on a 3-9 month horizon: the optionality is in lower medical trend and better chronic-care steering, with limited downside if ACCESS adoption is slower than expected.
• Pair trade: long managed care (HUM, CI) vs short a basket of weaker digital health point solutions; thesis is that reimbursement validation favors distribution and compliance moats over standalone app economics over the next 6-12 months.
• Speculative long CVS over 6-12 months: ACCESS strengthens the value of its care-management and pharmacy ecosystem, but size the position smaller because execution risk is higher and the earnings translation will be slower.
• Watchlist long on Verily-adjacent ecosystem beneficiaries for 12-18 months only on pullbacks after the initial launch hype fades; the better entry is after first reporting data confirms patient retention and outcome attribution.
• Avoid chasing small-cap digital health names into the launch: if reimbursement comes in below modeled lifetime value, multiple compression could outweigh any headline-driven rerating within 1-2 quarters.